Quantum Biopharma Ltd. — Interim / Quarterly Report 2020

Aug 11, 2020

6-K 1 form6k.htm FORM 6-K FSD Pharma Inc.: Form 6-K - Filed by newsfilecorp.com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2020

Commission File Number: 001-39152

FSD PHARMA INC. (Translation of registrant's name into English)

520 William Street Cobourg, Ontario K9A 3A5 (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ ] Form 40-F [ X ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

INCORPORATION BY REFERENCE

The Registrant’s Management’s Discussion and Analysis of Financial Condition and Results of Operations for the three and six months ended June 30, 2020 and 2019, included as Exhibit 99.1 of this Form 6-K and the Condensed Consolidated Interim Financial Statements for the three and six months ended June 30, 2020 and 2019 included as Exhibit 99.2 of this Form 6-K (Commission File No. 001-39152), furnished to the Commission on August 10, 2020, are incorporated by reference into the Registration Statement on Form F-10 (Commission File No. 333-236780) of the Registrant, FSD Pharma Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	FSD Pharma Inc.
	(Registrant)
Date: August 10, 2020	By: /s/ Donal Carroll
	Name: Donal Carroll
	Title: Chief Financial Officer

EXHIBIT INDEX

Exhibit	Description
99.1	Management’s Discussion and Analysis of Financial Condition and Results of Operations for the three and six months ended June 30, 2020 and 2019
99.2	Condensed Consolidated Interim Financial Statements for the three and six months ended June 30, 2020 and 2019
99.3	News Release dated August 7, 2020